Viewing Study NCT04079920


Ignite Creation Date: 2025-12-25 @ 4:09 AM
Ignite Modification Date: 2025-12-26 @ 3:07 AM
Study NCT ID: NCT04079920
Status: COMPLETED
Last Update Posted: 2025-06-08
First Post: 2019-08-05
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients
Sponsor: Pfizer
Organization:

Study Overview

Official Title: BASELINE VARIABLES PREDICTING TREATMENT RESPONSE AT 6 MONTHS IN ADULT RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5MG BID IN A NON-INTERVENTIONAL SETTING (TREAT - RA)
Status: COMPLETED
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: TREAT-RA
Brief Summary: This is a 24-month, prospective, non-interventional, multi-center study with primary aim to identify baseline characteristics of patients that predict response at 6 months of treatment. The study also aims to describe the treatment patterns of RA patients prescribed tofacitinib in a real-world setting and assess the effect of treatment on patient quality of life and physical function. Finally the study will assess the use of healthcare resources and costs in patients with RA treated with tofacitinib in Greece.

The planned recruitment period is 12 months. The planned observation period of each patient is 12 months. In this time period up to 4 visits will be documented.

The study will be reviewed and approved by the Central Regulatory Committee for NIS and IRB Board of each participating site
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
TREAT-RA OTHER Alias Study Number View